You are here

  • Home
  • Archive
  • Volume 77, Issue 2
  • Influence of disease activity and medications on offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus: a population-based study

Article Text

Article menu
Download PDFPDF
Clinical and epidemiological research
Extended report
Influence of disease activity and medications on offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus: a population-based study
  1. Carina Götestam Skorpen1,2,
  2. Stian Lydersen3,
  3. Inge-Margrethe Gilboe4,
  4. Johan Fredrik Skomsvoll5,
  5. Kjell Å Salvesen6,7,
  6. Øyvind Palm4,
  7. Hege Suorza Svean Koksvik5,
  8. Bente Jakobsen5,
  9. Marianne Wallenius1,5
  1. 1 Department of Neuromedicine and Movement Science (INB), Norwegian University of Science and Technology (NTNU), Trondheim, Norway
  2. 2 Department of Rheumatology, Ålesund Hospital, Ålesund, Norway
  3. 3 Regional Centre for Child and Youth Mental Health and Child Welfare (RKBU), Norwegian University of Science and Technology (NTNU), Trondheim, Norway
  4. 4 Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway
  5. 5 Norwegian National Advisory Unit on Pregnancy and Rheumatic Diseases, Department of Rheumatology, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
  6. 6 Department of Laboratory Medicine, Children’s and Women’s Health, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
  7. 7 Department of Obstetrics and Gynecology, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
  1. Correspondence to Carina Götestam Skorpen, Department of Rheumatology, Ålesund Hospital, 6026 Ålesund, Norway; carina.skorpen{at}ntnu.no

Abstract

Objectives Exploring the associations between disease activity and medications with offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus (SLE).

Methods Data from the Medical Birth Registry of Norway (MBRN) were linked with data from RevNatus, a nationwide observational register recruiting women with inflammatory rheumatic diseases. Singleton births in women with SLE included in RevNatus 2006–2015 were cases (n=180). All other singleton births registered in MBRN during this time (n=498 849) served as population controls. Z-score for birth weight adjusted for gestational age and gender was calculated. Disease activity was assessed using Lupus Activity Index in Pregnancy. We compared z-scores for birth weight, pre-eclampsia and preterm birth in cases with inactive disease, cases with active disease and population controls.

Results Z-scores for birth weight in offspring were lower in inactive (−0.64) and active (−0.53) diseases than population controls (−0.11). Inactive disease did not predict pre-eclampsia while active disease yielded OR 5.33 and OR 3.38 compared with population controls and inactive disease, respectively. Preterm birth occurred more often in inactive (OR 2.57) and active (OR 8.66) diseases compared with population controls, and in active compared with inactive disease (OR 3.36).

Conclusions SLE has an increased odds for low birth weight and preterm birth, amplified by active disease. The odds for pre-eclampsia is elevated in active, but not inactive disease. This calls for tight follow-up targeting inactive disease before and throughout pregnancy.

  • systemic lupus erythematosus
  • disease activity
  • treatment

https://doi.org/10.1136/annrheumdis-2017-211641

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Handling editor Tore K Kvien

    • Contributors CGS, IMG, JFS, KÅS and MW planned the study. CGS, IMG, ØP, HSSK, BJ and MW provided the data. CGS, SL and MW performed the analysis and drafted the paper. All authors contributed to editing the draft for content and approved the final version. CGS and MW had full access to all the data in the study and take responsibility for the integrity of the data and accuracy of the data analysis.

    • Funding The actual work was supported by the Liaison Committee for Education, Research and Innovation in Central Norway.

    • Competing interests None declared.

    • Ethics approval RevNatus was approved by the Regional Committee for Medical and Health Research Ethics (REK Mid-Norway). The present study and linking with MBRN was approved by REK Mid-Norway (2012/1905).

    • Provenance and peer review Not commissioned; externally peer reviewed.